Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for unmet medical needs, accelerates its expansion in Oncology with its first-in-class four-in-one Bacterial Cell and Gene Therapy AUP-55. The company’s first abstract, Effect of multi-targeting bacterial gene therapy on tumor regression and survival in mouse models of ovarian and intraperitoneal cancer, has been accepted and published on the prestigious American Society of Clinical Oncology (ASCO) website.
Read Aurealis Therapeutics abstract here.
This moment marks a pivotal turning point for Aurealis Therapeutics, as the company expands from its acclaimed focus on chronic wounds into the field of oncology and creates therapeutic solutions such as AUP-55 for ovarian, intraperitoneal or bladder cancer. The Aurealis Therapeutics Team is proud for the publication of its first abstract as it prepares for its participation in the ASCO Annual Meeting which will take place from 2-6 June in Chicago, IL.
About Aurealis Therapeutics
Aurealis Therapeutics AG is a Swiss-Finnish private clinical-stage synthetic biology company focusing on the development of lactic acid bacteria -based GMO cell and gene therapies. The company’s lead clinical assets are the first-in-class four-in-one cell and gene therapies AUP-16 for chronic wounds and AUP-55 for cancers. Aurealis therapies are based on proprietary technology involving genetically engineered Lactococcus Cremoris acting as millions of small immune-activating bioreactors producing multiple human therapeutic proteins (cytokines, growth factors, antibody fragments) to effectively and safely re-educate the distorted host immune microenvironment to a proper state.
For more information:
Laurent Décory, COO
Email: laurent@aurealistherapeutics.com
